



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

| APPLICATION NO. | FILING DATE | FIRST NAMED INVENTOR | ATTORNEY DOCKET NO. | CONFIRMATION NO. |
|-----------------|-------------|----------------------|---------------------|------------------|
| 10/650,591 | 08/27/2003 | Noubar B. Afeyan | COTH-P02-001 | 7918 |

56155 7590 07/29/2009
ROPES & GRAY LLP
PATENT DOCKETING Floor 39
One International Place
Boston, MA 02110-2624

| |
|----------|
| EXAMINER |
|----------|

MEAH, MOHAMMAD Y

| | |
|----------|--------------|
| ART UNIT | PAPER NUMBER |
|----------|--------------|

1652

| | |
|-----------|---------------|
| MAIL DATE | DELIVERY MODE |
|-----------|---------------|

07/29/2009

PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

| | | | |
|------------------------------|-------------------------------|-------------------------------|--|
| Office Action Summary | Application No. 10/650,591 | Applicant(s) AFEYAN ET AL. | |
| | Examiner MD. YOUNUS MEAH | Art Unit 1652 | |

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --
Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period **will** apply and **will** expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply **will**, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☒ Responsive to communication(s) filed on 17 April 2009.
- 2a) ☐ This action is **FINAL**. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 1,3-5,19-34 and 37-40 is/are pending in the application.
- 4a) Of the above claim(s) 3,28 and 29 is/are withdrawn from consideration.
- 5) ☐ Claim(s) _____ is/are allowed.
- 6) ☒ Claim(s) 1, 4-5,19-27, 30-34, 37-40 is/are rejected.
- 7) ☐ Claim(s) _____ is/are objected to.
- 8) ☐ Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on _____ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some * c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
2. ☐ Certified copies of the priority documents have been received in Application No. _____.
3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- | | |
|--|---|
| 1) <input checked="" type="checkbox"/> Notice of References Cited (PTO-892) | 4) <input type="checkbox"/> Interview Summary (PTO-413) |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948) | Paper No(s)/Mail Date. _____. |
| 3) <input checked="" type="checkbox"/> Information Disclosure Statement(s) (PTO/SB/08) | 5) <input type="checkbox"/> Notice of Informal Patent Application |
| Paper No(s)/Mail Date <u>3/25/09, 6/15/09</u> . | 6) <input type="checkbox"/> Other: _____. |

DETAILED ACTION

Claims 1, 3-5, 19-34 and 37-40 are pending. With supplemental amendment, filed 4/17/09, in response the final action, mailed on 1/26/2009, the applicants amended claims 1, 21, 23-25, 28, 30-31 and 33-34 and canceled claims 41 and 14-17. Claims 3 and 28-29 remain withdrawn.

Applicants' amendment of 4/17/09 is considered. Rejections and/or objections not reiterated from previous office actions are hereby withdrawn.

Objection

Claim 4 is objected for the recitation of "selected from among:- -". It should be amended to recite "selected from the group consisting of...". Appropriate correction is required.

Claim 24 is objected for the recitation of " selected from among: - -". It should be amended to recite "selected from the group consisting of...". Appropriate correction is required.

Claim Rejection 35 U.S.C 112 2nd paragraph

The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

Claims 1, 4-5, 19-27, 30-34 and 37-40 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

Claims 1 and 4-5, 19-27, 30-34, 37-40 (depend on claim 1) are rejected under 35 U.S.C. 112, second paragraph, as being indefinite in the recitation of the phrase in claim 1 "address site" because it is unclear what is the "address site". If it is merely a site which can be targeted by something, the term "address" makes it confusing. It should simply say "site" unless the term "address" is further defining where/what the site is. Correction is required.

Claim 1 is rejected under 35 U.S.C. 112, second paragraph, as being indefinite in the recitation of the phrase "resistant to cleavage by said protease domain"] because the resulting claim does not set forth the metes and bound of the desired patent protection. The term "resistant" is a term of degree. It is unclear how much cleavage is required for the adzyme to be considered "resistant". The specification fails to disclose a definition of what is considered "resistant". Therefore, one of skill in the art is not able to determine the boundary of the claim.

For the examination purpose only, the phrase is ignored because no reasonable interpretation could be made.

Claim 19 is rejected under 35 U.S.C. 112, second paragraph, as being indefinite in the recitation of the phrase " extracellular polypeptide" because it is unclear how an extracellular polypeptide is different from the polypeptide as any isolated polypeptide could be considered an extracellular polypeptide because the isolation step would separate it from the cell it was made. Correction is required.

Claim 20 is rejected under 35 U.S.C. 112, second paragraph, as being indefinite in the recitation of " the adzyme is resistant to autocatalyzed proteolysis at a concentration equal to –" because it does not further limit the subject matter of the claim from that of the previous claim 1. There is no actual value in the claim for the concentration of the adzyme in a solution to be administered to a subject. Therefore, it is unclear what it means by "the adzyme is resistant to autocatalyzed proteolysis at a concentration equal to" something that is undefined.

Claim 20 is rejected under 35 U.S.C. 112, second paragraph, as being indefinite in the recitation of the phrase "resistant to autocatalyzed--" , because the resulting claim does not set forth the metes and bounds of the desired patent protection. The term "resistant" is a term of degree. It is unclear how much cleavage is required for the adzyme to be considered "resistant". The specification fails to disclose a definition of what is considered "resistant". Therefore, one of skill in the art is not able to determine the boundary of the claim.

Claim 25 is indefinite in the recitation of "enzyme construct" and "polypeptide factor" as there is no antecedent basis for enzyme construct and polypeptide factor in claim 21, or claim 1 from which this claim depends. For examination purposes claim 25 will be interpreted as if the claim does not recite "and said enzyme.....factor".

Claim 26 is rejected under 35 U.S.C. 112, second paragraph, as being indefinite in the recitation of "polypeptide including an antigen binding site thereof". It is unclear

which antigen it refers to. It is unclear if the term "polypeptide including an antigen binding site thereof" is intended to refer to a polypeptide comprising a binding site for said substrate or not. If it refers to a polypeptide comprising a binding site for the substrate, then claim should recite "a polypeptide comprising a binding site for the substrate". Correction is required.

Claim 27 is rejected under 35 U.S.C. 112, second paragraph, as being indefinite in the recitation of "targeting domain----- consisting of monoclonal antibody, **a Fab and a F(ab)₂**, an sc Fv..." because it is unclear whether the claim refers to a targeting domain which is a complex of a Fab with a F(ab)₂ (a Fab and F(ab)₂) or if it refers to a targeting domain which is either a Fab or a F(ab)₂. If claim refers to a targeting domain which is either a Fab or a F(ab)₂, the claim should recite "monoclonal antibody, a Fab, a F(ab)₂, an sc Fv..." instead of "monoclonal antibody, a Fab and a F(ab)₂, an sc Fv..." as is currently written. Correction is required.

Claim Rejection - 35 U.S.C 103a

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

Claims 1, 4, 14, 19-21, 22-27, 30, 33-34, 37 and 38 were rejected under 35 U.S.C. 103(a) by Davis et al. (WO 00/64485) in view of, Bhatia et al (Intl. J. Cancer 2000, 85, 571-57) and Whitcomb et al. (US PAT 6406846) in the non-final office action

of 01/26/2009. This rejection is withdrawn because of the amendments of the claims 1, 4-5, 19-27, 30-34 and 37-40 by the applicants. However Davis et al (WO 00/64485) is used for a new 35 U.S.C. 103(a) rejection for the amended claims as shown below:

Claims 1, 4, 19-27, 30-34 and 37 are rejected under 35 U.S.C. 103(a) by Davis et al (WO00/64485) in view of Chamow et al (Trend Biotech, 1996, 14, pp52-60).

Davis et al. teach fusion proteins wherein enzymes (serine protease, chymotrypsin, matrix metaloprotease, etc) which catalyze degradation of a specific target are conjugated to targeting (bind to the target) domains, such as ligand, antibody (page 23, lines 15-30, page 8 lines 20-25, page 15 lines 9-52), wherein protease is conjugated to immunoglobulin, Fab or F(ab)₂. Davis et al teach that resulting chimeric protein has greater (catalytic, page 8) activity than the unconjugated molecule. The chimeric protein of Davis et al. binds to the target and antagonize/inhibit /degrade a wide variety of receptors and/or intermediary signaling molecules such as cytokines, EGF-like factors, etc (page 28). Davis et al. use the fusion protein as a pharmaceutical composition (pages 51-56).

However Davis et al do not teach a fusion complex comprising fusion protein comprising protease conjugated to constant portion of immunoglobulin heavy chain and second fusion protein comprising a targeting domain conjugated to constant portion of an immunoglobulin heavy chain.

Chamow et al teach bispecific immunoadhesins (immunoglobulin fusion protein) comprising two different proteins having different functions each conjugated to each pair of constant region of immunoglobulin (table 1 and Fig 3, P-selectin-IgG and E-

Art Unit: 1652

selectin-IgG). It is well known in the art the advantages of using the immunoglobulin constant region to make fusion proteins (see, Chamow et al, Trend Biotech, 1996, 14, pp52-60, and Ashkenazi et al, Current Opin. of Immunol. 1997, 9, pp 195-200): such as joining the fusion partner to immunoglobulin facilitates proper folding of domains and function (page 52 right column 2nd parag. Chamow et al) by providing antibody type structural properties (by bring them closer, Ashkenazi et al, page 196 left column 2nd parag) and increase size often extend in vivo half-life (Ashkenazi et al, page 196 left column 2nd parag.). Therefore, one of skill in the art would have been **motivated** to make the fusion complex comprising a protease conjugated to constant portion of immunoglobulin heavy chain and a targeting domain conjugated to constant portion of an immunoglobulin heavy chain so that said catalytic domain and targeting domain fusion complex comprise proper folding (via immunoglobulin dimeric binding partner) so that their effective concentration and function is optimized at the target site.

As such it would have been obvious to one of ordinary skill in the art to use a protease to make a fusion protein (adzyme) as taught by Davis et al and Chamow et al, wherein protease is conjugated to the constant region of an immunoglobulin heavy chain and a targeting domain comprising an antibody light chain is conjugated to the constant portion of another immunoglobulin heavy chain and use the resulting adzyme to inactivate substrate polypeptides by catalyzing the proteolytic cleavage of the said substrate polypeptide. One of ordinary skill in the art at the time of the invention was made would have had a reasonable expectation for success for making an adzyme comprising a fusion complex comprising protease conjugated to constant portion of

immunoglobulin heavy chain and a targeting domain conjugated to constant portion of an immunoglobulin heavy chain, because the DNA molecules encoding many proteases are known, and the molecular biology techniques required to make a recombinant fusion proteins are well known in the art (Ashkenazi et al, Current Opin. of Immunol. 1997, 9, pp 195-20). Claims 4, 21-22, and 30-34 are included in rejection because the adzyme of Davis et al. and Chamow et al. meets all the structure limitations of the claimed invention and the additional limitations in claims 4, 21-22, and 30-34 appears to be intended uses of the claimed invention. Intended use limitations do not carry a patentable weight. Therefore, the invention as a whole would have been *prima facie* obvious to a person of ordinary skill in the art at the time the invention was made.

Claim 5 is rejected under 35 U.S.C. 103(a) as being unpatentable over Davis et al. (WO 00/64485) in view of Chamow et al (Trend Biotech, 1996, 14, pp52-60) as applied to claims 1, 4, 19-27, 30-34 and 37 above, and further in view of Dolinar et al. (*Food tecnol and biotech.* 2000, 38, 5-9).

Davis et al. and Chamow et al are described above. However neither Davis et al. nor Chamow et al. teach purification of a fusion protein comprising a protease domain using a reversible protease inhibitor.

Use of protease inhibitor in protein purification is well known in prior art. Dolinar et al. teach MMTS (methyl methane-thiosulfonate), a reversible protease inhibitor in the purification and refolding of a cystine proteinase type protein (page 6, column 2 last parag.). Therefore, one of skill in the art would have been **motivated to** purify a fusion

protein complex comprising a protease using a protease inhibitor so that said fusion protein complex would not be cleaved by the protease.

As such it would have been obvious to one of ordinary skill in the art to use a protease inhibitor to purify the protease-containing fusion protein complex of Davis et al. and Chamow et al. described above. One of ordinary skill in the art has a reasonable expectation of success at obtaining an adzyme which is resistant to autocatalytic proteolysis in view of the teachings of Dolinar et al. Therefore, the invention as a whole would have been prima facie obvious to a person of ordinary skill in the art at the time the invention was made.

Claims 38-40 are rejected under 35 U.S.C. 103(a) as being unpatentable over 35 U.S.C. 103(a) by Davis et al. (WO 00/64485) in view of Chamow et al (Trend Biotech, 1996, 14, pp52-60) as applied to claims 1, 4, 19-27, 30-34 and 37 above, and further in view of Sanderson et al. (Medic. Res Rev 1999, 19, 179-197).

Davis et al. and Chamow et al. are described above. However, neither Davis et al. nor Chamow et al. teach a pharmaceutical preparation comprising a reversible inhibitor safe to humans.

Sanderson *et al.* (Medic. Res Rev 1999, 19, 179-197) teach a small molecule non-covalent binding protease inhibitor used in a pharmaceutical composition which is reversible and safe to humans (abstract).

Use of protease inhibitors in protein samples is well known in prior art because proteases catalyze the degradation of protein molecules (abstract, page 1, Sanderson

et al).). Therefore, in order to inhibit the protease degradation of a pharmaceutical preparation comprising the adzyme of Davis et al. and Chamow et al., one of skill in the art would have been **motivated** to add a reversible protease inhibitor that is safe to humans as taught by Sanderson *et al.* to extend the shelf life of the adzyme.

As such it would have been obvious to one of ordinary skill in the art to make a pharmaceutical preparation comprising the adzyme of Davis et al. and Chamow et al. and combine it with a reversible protease inhibitor as taught by Sanderson et al. so that said pharmaceutical preparation is safe to humans and remains effective. One of ordinary skill in the art has a reasonable expectation of success at making such pharmaceutical composition in view of the fact that protease inhibitors which are safe for humans are known and used in the art as evidenced by Sanderson et al. Therefore, the invention as a whole would have been *prima facie* obvious to a person of ordinary skill in the art at the time the invention was made.

Double Patenting Rejection

The provisional rejection of claims 1, 4-5, 19-27, 30-34, 37-40 under the judicially created doctrine of obviousness-type double patenting as being unpatentable over claims 1, 4-5, 19-27, 30-34, 37-40 of copending Application No.10/792498 is maintained.

Examiner agrees with applicant that the provisional double patenting rejections may be withdrawn when all claims are otherwise allowable if the copending application is not allowable. All the examined claims of the instant application are rejectable on

Art Unit: 1652

other grounds. Since applicant did not submit terminal disclaimer, the rejections will be maintained.

The provisional rejection of claims 1, 4-5, 19-27, 30-34, 37-40 under the judicially created doctrine of obviousness-type double patenting as being unpatentable over claims 1, 4-38, 40-46, 52-60, 66-104, 107-134 of copending Application No.10/650,592 is withdrawn because, after amendment of claims 1, 4-5, 19-27, 30-34, 37-40 of the instant application, none of the claims of Application No: 10/650,592 render the claims of instant application obvious.

Allowable Subject Matter/Conclusion

None of the claims are allowable

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Mohammad Meah whose telephone number is 571-272-1261. The examiner can normally be reached on 8:30-5PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Andrew Wang can be reached on 571-272-0811. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Mohammad Younus Meah
Examiner, Art Unit 1652

/Delia M. Ramirez/
Primary Examiner, Art Unit 1652

Application/Control Number: 10/650,591
Art Unit: 1652

Page 12